Compare Marriott International Inc (MAR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Recursion Pharmaceuticals Inc — how do they compare? Marriott International Inc trades at $349.51 (market cap $90.86B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.78B). The key difference: Marriott International Inc is far larger — about 51× Recursion Pharmaceuticals Inc's market cap, and Marriott International Inc pays a 0.84% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MAR | RXRX | |
|---|---|---|
Market Cap | $90.86B | $1.78B |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $6.79 |
52-Week Low | $257.97 | $2.84 |
Enterprise Value | $108.17B | $1.30B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $353.91, down 1.6% in the last 24 hours, with a bearish technical signal. The stock shows strong profitability with a net income margin of 9.62% and ROE of 1,446.77%, but faces high valuation ratios like a P/E of 36.64. Recent Q2 2026 earnings beat estimates at $3.19 per share, and the company raised its 2026 outlook, though revenue missed expectations. A quarterly dividend of $0.73 per share was declared, payable on June 30, 2026.
The outlook is mixed: robust fee growth and a record pipeline support upside, but elevated debt and premium valuation pose risks. Analysts are generally positive with a consensus price target of $387.31, though near-term volatility may persist due to macroeconomic headwinds and regional weaknesses in the Middle East.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
